Physician profile
Putao Cen
NPI 1891947735
$720,397.08
in general payments reported to CMS, 2019-2025
30 companies · $147K in 2025
The $147K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169K · 2020: $36K · 2021: $22K · 2022: $72K · 2023: $146K · 2024: $129K · 2025: $147K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $310K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $60K · Travel and Lodging: $33K · Food and Beverage: $10K · Consulting Fee: $7,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $310,193.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $60,435.00 |
| Travel and Lodging | $33,492.45 |
| Food and Beverage | $10,071.04 |
| Consulting Fee | $7,175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $225,440.80 | 2019-2025 | Keytruda, Welireg |
| Eisai INC. | $151,382.25 | 2019-2025 | |
| Taiho Oncology, INC. | $99,266.20 | 2019-2025 | |
| Astellas Pharma US INC | $80,305.83 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Lilly USA, LLC | $69,830.29 | 2019-2022 | |
| Seagen INC. | $59,102.50 | 2020-2023 | Padcev |
| Pfizer INC. | $16,137.14 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $4,535.90 | 2019-2022 | |
| Exelixis INC. | $4,099.97 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,052.31 | 2024-2025 | Imfinzi |
| Ipsen Biopharmaceuticals, INC | $3,031.28 | 2024-2025 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $1,166.48 | 2019-2023 | |
| Sirtex Medical INC | $917.73 | 2021-2024 | Sir-Spheres Microspheres |
| Tempus Ai, INC | $562.98 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $249.96 | 2023-2024 | Pemazyre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $153.42 | 2019-2025 | Erleada |
| E.R. Squibb & Sons, L.L.C. | $142.62 | 2025 | Opdivo |
| Aveo Pharmaceuticals, INC. | $134.87 | 2024 | |
| Gilead Sciences, INC. | $132.01 | 2023-2024 | Trodelvy |
| Sumitomo Pharma America, INC. | $123.69 | 2024 | Orgovyx |
| Immunocore Limited | $120.78 | 2025 | Kimmtrak |
| Pharmacosmos Therapeutics INC. | $117.32 | 2024 | Monoferric |
| Astellas Pharma Global Development | $110.00 | 2024 | Padcev |
| Intera Oncology, INC | $103.34 | 2024 | Intera |
| Daiichi Sankyo INC. | $41.86 | 2025 | Enhertu |
| Tactile Systems Technology INC | $41.36 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Genmab U.S., INC. | $29.98 | 2024 | Epkinly |
| Janssen Scientific Affairs, LLC | $25.72 | 2022 | |
| Celgene Corporation | $21.72 | 2024 | Reblozyl |
| Abbvie INC. | $16.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Putao Cen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.